Publications

Jennifer A. Woyach, Farrukh Awan, Ian W. Flinn, Jesus G. Berdeja, Elizabeth Wiley, Sharmeen Mansoor, Ying Huang, Gerard Lozanski, Paul A. Foster and John C. Byrd A phase I trial of the Fc engineered CD19 antibody XmAb®5574(MOR00208) demonstrates safety and preliminary efficacy in relapsed chronic lymphocytic leukemia Blood doi:10.1182/blood-2014-08-593269 Prepublished online October 9, 2014

Seung Y. Chu, Karen Yeter, Roshan Kotha, Erik Pong, Yvonne Miranda, Sheryl Phung, Hsing Chen, Sung-Hyung Lee, Irene Leung, Christine Bonzon, John R. Desjarlais, William Stohl, David E. Szymkowski (2014) Suppression of Rheumatoid Arthritis B Cells by XmAb5871, an Anti-CD19 Antibody That Coengages B Cell Antigen Receptor Complex and Fc Gamma Receptor IIb Inhibitory Receptor Arthritis & Rheumatology, 66: 1153–1164. doi: 10.1002/art.38334

Matthew J. Bernett, Seung Y. Chu, Irene Leung, Gregory L. Moore, Sung-Hyung Lee, Erik Pong, Hsing Chen, Sheryl Phung, Umesh S. Muchhal, Holly M. Horton, Greg A. Lazar, John R. Desjarlais, David E. Szymkowski (2013) Immune suppression in cynomolgus monkeys by XPro9523: An improved CTLA4-Ig fusion with enhanced binding to CD80, CD86 and neonatal Fc receptor FcRn. Volume 5, Issue 3, May/June 2013, http://dx.doi.org/10.4161/mabs.23976 Abstract The CTLA4-Ig fusion proteins abatacept and belatacept are clinically proven …

Tai YT, Horton HM, Kong SY, Pong E, Chen H, Cemerski S, Bernett MJ, Nguyen DH, Karki S, Chu SY, Lazar GA, Munshi NC, Desjarlais JR, Anderson KC, Muchhal US (2012) Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector function. Blood. 2012 Jan 13. [Epub ahead of print]

Chu SY, Horton H, Pong E, Leung I, Chen H, Nguyen D-H, Bautista C, Muchhal US, Bernett M, Moore GL, Szymkowski DE, Desjarlais JR (2012) Reduction of Total IgE by Targeted Coengagement of IgE B cell Receptor and FcgRIIb with Fc-Engineered Antibody. J Allergy Clin Immunol, doi:10.1016/j.jaci.2011.11.029

Cemerski S, Chu SY, Moore GL, Muchhal US, Desjarlais JR, Szymkowski DE (2012) Suppression of mast cell degranulation through a dual-targeting tandem IgE-IgG Fc domain biologic engineered to bind with high affinity to FcgRIIb. Immunol Lett, in press.

Moore GL, Bautista C, Pong E, Nguyen DH, Jacinto J, Eivazi A, Muchhal US, Karki S, Chu SY, Lazar GA (2011) A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigens. MAbs. Nov 1;3(6). [Epub ahead of print].

JR Desjarlais and GA Lazar (2011) Modulation of antibody effector function. Experimental Cell Research 317(9)1278-1285 …

Horton HM, Chu SY, Ortiz EC, Pong E, Cemerski S, Leung IW, Jacob N, Zalevsky J, Desjarlais JR, Stohl W, Szymkowski DE (2011) Antibody-Mediated Coengagement of FcgRIIb and B Cell Receptor Complex Suppresses Humoral Immunity in Systemic Lupus Erythematosus. J Immunol. 2011 Apr 1 …

Maillet I, Schnyder-Candrian S, Couillin I, Quesniaux VF, Erard F, Moser R, Fleury S, Kanda A, Dombrowicz D, Szymkowski DE, Ryffel B (2011) Allergic Lung Inflammation is Mediated by Soluble TNF and Attenuated by Dominant-negative TNF Biologics. Am J Respir Cell Mol Biol. 2011 Feb 4. [Epub ahead of print] …

Holly M. Horton, Matthew J. Bernett, Matthias Peipp, Erik Pong, Sher Karki, Seung Y. Chu, John O. Richards, Hsing Chen, Roland Repp, John R. Desjarlais, and Eugene A. Zhukovsky (2010) Fc-engineered anti-CD40 antibody enhances multiple effector functions and exhibits potent in vitro and in vivo antitumor activity against hematological malignancie Blood, Jul 2010; doi:10.1182/blood-2010-01-265280 …

Moore GL, Chen H, Karki S, and Lazar GA (2010) Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions. MAbs 2(2):181-189. …

Awan FT, Lapalombella R, Trotta R, Butchar JP, Yu B, Benson DM, Roda JM, Cheney C, Mo X, Lehman A, Jones J, Flynn J, Jarjoura D, Desjarlais JR, Tridandapani S, Caligiuri MA, Muthusamy N, and Byrd JC (2010). CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain–engineered monoclonal antibody. Blood 115(6): 1204-1213. …

Zalevsky J, Chamberlain AK, Horton HM, Karki S, Leung IW, Sproule TJ, Lazar GA, Roopenian DC, and Desjarlais JR (2010). Enhanced antibody half-life improves in vivo activity. Nat Biotechnol 28(2):157-9. …

Bernett MJ, Karki S, Moore GL, Leung IW, Chen H, Pong E, Nguyen DH, Jacinto J, Zalevsky J, Muchhal US, Desjarlais JR, and Lazar GA (2010) Engineering Fully Human Monoclonal Antibodies from Murine Variable Regions. J Mol Biol 396(5):1474-90. …

Zalevsky J, Leung IW, Karki S, Chu SY, Zhukovsky EA, Desjarlais JR, Carmichael DF, Lawrence CE (2009) The impact of Fc engineering on an anti-CD19 antibody: increased Fc gamma receptor affinity enhances B-cell clearing in nonhuman primates. Blood 113:3735-3743 …

Holly M. Horton, Matthew J. Bernett, Erik Pong, Matthias Peipp, Sher Karki, Seung Y. Chu, John O. Richards, Igor Vostiar, Patrick F. Joyce, Roland Repp, John R. Desjarlais, and Eugene A. Zhukovsky (2008) Potent In vitro and In vivo Activity of an Fc-Engineered Anti-CD19. Cancer Research 68(19):8049-8057. …

Chu SY, Vostiar I, Karki S, Moore GL, Lazar GA, Pong E, Joyce PF, Szymkowski DE, Desjarlais JR (2008) Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and FcgammaRIIb with Fc-engineered antibodies. Molecular Immunology 45(15):3926-33. …

John O. Richards, Sher Karki, Greg A. Lazar, Hsing Chen, Wei Dang, and John R. Desjarlais (2008) Optimization of antibody binding to FcgRIIa enhances macrophage phagocytosis of tumor cells. Molecular Cancer Therapeutics 7: 2517-2527. …

Desjarlais JR, Lazar GA, Zhukovsky EA, Chu SY (2007) Optimizing engagement of the immune system by anti-tumor antibodies: an engineer’s perspective. Drug Discovery Today 12(21-22): 898-910. …

Zhu M.M., Mollet M., and Hubert R.S. (2007) Industrial Production of Therapeutic Proteins: Cell Lines, Cell Culture, and Purification. Industrial Chemistry and Biotechnology, Edited by Kent and Riegel, 11th Edition, Chapter 32, p1421-1448, Springer Press, The Netherlands. …

Jonathan Zalevsky, Thomas Secher, Sergei A. Ezhevsky, Laure Janot, Paul M. Steed, Christopher O’Brien, Araz Eivazi, James Kung, Duc-Hanh T. Nguyen, Stephen K. Doberstein, Francois Erard, Bernhard Ryffel, and David E. Szymkowski (2007) Dominant-Negative Inhibitors of Soluble TNF Attenuate Experimental Arthritis without Suppressing Innate Immunity to Infection. The Journal of Immunology 179, 1872-1883.

Lazar G.A., Desjarlais J.R., Jacinto J., Karki S., and Hammond P.W. (2007) A molecular immunology approach to antibody humanization and functional optimization. Molecular Immunology 44, 1986-1998. …

Lazar G.A., Dang W., Karki S., Vafa O., Peng J.S., Hyun L., Chan C., Chung H.S., Eivazi A., Yoder S.C., Vielmetter J., Carmichael D.F., Hayes R.J., and Dahiyat, B.I. (2006) Engineered Antibody Fc Variants with Enhanced Effector Function. Proc Natl Acad Sci USA 103(11), 4005-4010.…

Barbosa, M.D.F.S., Vielmetter, J., Seung, C., Smith, D.D., and Jacinto, J. (2006) Clinical link between MHC class II haplotype and interferon-beta (IFN-B) immunogenicity. Clinical Immunology, 118, 42-50 …

Szymkowski D.E. (2005) Creating the next generation of protein therapeutics through rational drug design. Current Opinion in Drug Discovery & Development 8(5), 590-600 …

Vielmetter J. et al. (2005) Data management solutions for protein therapeutic research and development, Drug Discovery Today: Biosilico, 10(15), 1065-1071 …

Szymkowski D.E. (2005) Timely lessons for target-based discovery of anti-inflammatory drugs. Drug Discovery Today, 109(1), 14-17 …

Szymkowski D.E. (2004) Rational optimization of proteins as drugs: A new era of ‘medicinal biology’. Drug Discovery Today, 9(9), 381-383…

Zhukovsky E.A. and Morse R.J. (2004) Pleiotropy: the BAFFling truth of the TNF superfamily. Drug Discovery Today: Targets, vol.3, No. 6, pp. 225-227…

Chirino A. J. and Mire-Sluis A. (2004) Characterizing biological products and assessing comparability following manufacturing changes. Nature Biotechnology, 22(11), 1383-91 …

Zhukovsky E.A., Lee J.O., Villegas M., Chan C., Chu S., Mroske C. (2004) TNF ligands: is TALL-1 a trimer or a virus-like cluster? Nature, 427(6973), 413-4 …

Chirino, A.J., Ary, M.L., Marshall, S.A. (2004) Minimizing the immunogenicity of protein therapeutics. Drug Discovery Today, 9(2), 82-90 …

Steed, P.M. et al. (2003) Inactivation of TNF Signaling by Rationally Designed Dominant-Negative TNF Variants. Science, 301, 1895-1898(Full Text) …

Lazar, G.A., Marshall, S.A., Plecs, J.J., Mayo, S.L., Desjarlais, J.R. (2003) Designing proteins for therapeutic applications. Curr Opin Struct Biol, 13(4), 513-8 …

Szymkowski D.E. (2003) Chemical genomics versus orthodox drug development. Drug Discovery Today, 8(4), 157-159 …

Marshall, S.A., Lazar, G.A., Chirino, A.J., Desjarlais, J.R., (2003) Rational design and engineering of therapeutic proteins. Drug Discovery Today, 8(5), 212-2 …

Filikov, A.V., Hayes, R.J., Luo, P., Stark, D.M., Chan, C., Kundu, A., and Dahiyat, B.I. (2002) Computational stabilization of human growth hormone. Protein Science, 11, 1452 …

Hayes, R.J., Bentzien, J., Ary, M.L., Hwang, M.Y., Jacinto, J.M., Vielmetter, J., Kundu, A., and Dahiyat, B.I. (2002) Combining computational and experimental screening for rapid optimization of protein properties. Proc Natl Acad Sci USA, 99, 15926 …

Luo, P, Hayes, R.J., Chan, C., Stark, D.M., Hwang, M.Y., Jacinto, J. M., Juvvadi, P., Chung, H.S., Kundu, A., Ary, M.L., and Dahiyat, B.I. (2002) Development of a cytokine analog with enhanced stability using computational ultrahigh throughput screening. Protein Science, 11(5), 1218 …

Dahiyat, B. I., (1999) In silico design for protein stabilization. Curr. Op. Biotechnol., 10, 387 …

Malakauskas, S. M., and Mayo, S. L., (1998) Design, structure and stability of a hyperthermophilic protein variant. Nature Struc. Biol., 5, 470 …

Dahiyat, B., Gordon, D., and Mayo, S. L. (1997) Automated design of the surface of protein helices. Protein Sci., 6, 1333 …

Dahiyat, B. I., and Mayo, S. L., (1997) Probing the role of packing specificity in protein design. Proc Natl Acad Sci U S A, 94, 10172 …

Dahiyat, B. I., and Mayo, S. L., (1997) De novo protein design: fully automated sequence selection. Science, 278, 82 …

Dahiyat, B. I., and Mayo, S. L., (1996) Protein design automation. Protein Sci., 5, 895 …